 |
Ability Pharmaceuticals |
ABTL0815 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
1NRP |
|
ABTL0815
Therapeutic area:
Cancer
|
|
Ability Pharmaceuticals |
ABTL0812 |
Biodrugs/ Drugs |
Cancer |
Lung, Endometrial and Pancreatic Cancer |
4PhII |
|
ABTL0812
Therapeutic area:
Cancer
|
 |
Accure Therapeutics |
ACT-03 |
Biodrugs/ Drugs |
Central Nervous System |
Epilepsy |
1NRP |
|
ACT-03
Therapeutic area:
Central Nervous System
|
|
Accure Therapeutics |
ACT-02 |
Biodrugs/ Drugs |
Central Nervous System |
Cognitive Impairment associated to neurodegenerative and psychiatric diseases (schizophrenia, Parkinson's disease) |
2RP |
Spain |
ACT-02
Therapeutic area:
Central Nervous System
|
|
Accure Therapeutics |
ACT-01 |
Biodrugs/ Drugs |
Central Nervous System
Ophthalmology and optometry |
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis |
3PhI |
|
ACT-01
Therapeutic area:
Central Nervous System
Ophthalmology and optometry
|
 |
ALGENEX (Alternative Gene Expression S.L.) |
PCV2 vaccine |
Vaccines |
Infections |
Porcine Circovirus |
2RP |
|
PCV2 vaccine
Therapeutic area:
Infections
|
|
ALGENEX (Alternative Gene Expression S.L.) |
RHDV vaccine |
Vaccines |
Infections |
Rabbit Hemorrhagic Disease Virus |
6Reg. |
|
RHDV vaccine
Therapeutic area:
Infections
|
|
ALGENEX (Alternative Gene Expression S.L.) |
Animal Influenza |
Vaccines |
Infections |
- |
2RP |
|
Animal Influenza
Therapeutic area:
Infections
|
|
ALGENEX (Alternative Gene Expression S.L.) |
BDV vaccine |
Vaccines |
Infections |
Bovine Diarrhea Virus |
1NRP |
|
BDV vaccine
Therapeutic area:
Infections
|
|
ALGENEX (Alternative Gene Expression S.L.) |
COVID19 vaccine |
Vaccines |
Infections |
COVID19 vaccine with several proteins |
1NRP |
|
COVID19 vaccine
Therapeutic area:
Infections
|
 |
Almirall |
Terbinafine, ALM12834 |
Biodrugs/ Drugs |
Dermatology |
Onychomycosis |
6Reg. |
|
Terbinafine, ALM12834
Therapeutic area:
Dermatology
|
|
Almirall |
BNZ-01 |
Biodrugs/ Drugs |
Cancer
Dermatology |
Refractory cutaneous T-cell lymphoma |
4PhII |
|
BNZ-01
Therapeutic area:
Cancer
Dermatology
|
|
Almirall |
Finasteride, ALM12845 |
Biodrugs/ Drugs |
Dermatology |
Androgenetic Alopecia |
6Reg. |
|
Finasteride, ALM12845
Therapeutic area:
Dermatology
|
|
Almirall |
Tirbanibulin, ALM14789 |
Biodrugs/ Drugs |
Dermatology |
Actinic keratosis |
6Reg. |
|
Tirbanibulin, ALM14789
Therapeutic area:
Dermatology
|
|
Almirall |
Lebrikizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Atopic dermatitis |
5PhIII |
|
Lebrikizumab
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
 |
Aptatargets |
ApTOLL-03 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Multiple Sclerosis |
1NRP |
|
ApTOLL-03
Therapeutic area:
Autoimmune & Inflammation
|
|
Aptatargets |
ApTOLL-01 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System |
Acute ischemic stroke
Acute coronary syndrome |
3PhI |
|
ApTOLL-01
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
|
 |
APTUS Biotech |
AptaMnk |
Biodrugs/ Drugs |
Cancer |
Breast cancer treatment based on aptamers |
1NRP |
|
AptaMnk
Therapeutic area:
Cancer
|
 |
Araclon Biotech |
ABvac40 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
4PhII |
|
ABvac40
Therapeutic area:
Central Nervous System
|
 |
Archivel Farma |
RUTI |
Vaccines |
Infections |
Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS- COV-2 Infection in Healthcare Workers |
2RP |
Spain |
RUTI
Therapeutic area:
Infections
|
|
Archivel Farma |
RUTI |
Vaccines |
Infections |
Safety of RUTI® Vaccination in MDR-TB Patients |
4PhII |
Ucrania |
RUTI
Therapeutic area:
Infections
|
|
Archivel Farma |
RUTI |
Vaccines |
Cancer |
Bladder cancer. |
3PhI |
|
RUTI
Therapeutic area:
Cancer
|
|
Archivel Farma |
RUTI® |
Vaccines |
Infections |
Active tuberculosis - Latent Tuberculosis |
4PhII |
Europe and South Africa |
RUTI®
Therapeutic area:
Infections
|
 |
Arthex Biotech |
ARTHEx-01 |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Myotonic dystrophy type 1 (DM1) |
1NRP |
|
ARTHEx-01
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
 |
ATRYS HEALTH |
NILO1 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Brain tumor and brain lesions |
1NRP |
Spain |
NILO1
Therapeutic area:
Cancer
Central Nervous System
|
 |
Bionos Biotech SL |
Pytren 4Q - Scorpio Therapeutics |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Pytren 4Q se presenta como una terapia sintomática para la enfermedad huérfana de Huntington mediante la reducción de los síntomas por activación y estimulación de la autofagia y de la actividad proteasómica. Es un compuesto antioxidante, activador de la |
1NRP |
|
Pytren 4Q - Scorpio Therapeutics
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
 |
DIOMUNE SL |
IV1303 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections |
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV |
2RP |
|
IV1303
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
|
 |
ENTRECHEM |
EC-8042 iv for Triple negative breast cancer |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-8042 iv for Triple negative breast cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for TNBC |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-70124 po for TNBC
Therapeutic area:
Cancer
|
|
ENTRECHEM |
Brasilicardin analogs |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Immunosupression |
1NRP |
|
Brasilicardin analogs
Therapeutic area:
Autoimmune & Inflammation
|
|
ENTRECHEM |
EC-70124 po for prostate cancer |
Biodrugs/ Drugs |
Cancer |
Castration resistant prostate cancer |
2RP |
|
EC-70124 po for prostate cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for liposarcoma |
Biodrugs/ Drugs |
Cancer |
liposarcoma myxoide |
2RP |
|
EC-8042 iv for liposarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for AML |
Biodrugs/ Drugs |
Cancer |
Acute myeloid leukemia |
2RP |
|
EC-70124 po for AML
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Ewing sarcoma |
Biodrugs/ Drugs |
Cancer |
Solid tumours |
2RP |
|
EC-8042 iv for Ewing sarcoma
Therapeutic area:
Cancer
|
 |
FERRER |
FAB-117 |
Gene / Cell Therapy |
Central Nervous System |
Spinal Cord Injury |
4PhII |
|
FAB-117
Therapeutic area:
Central Nervous System
|
|
FERRER |
SP1440 |
Biodrugs/ Drugs |
Central Nervous System |
Small Molecular. Schizophrenia and cognitive improvement |
2RP |
|
SP1440
Therapeutic area:
Central Nervous System
|
|
FERRER |
FAB-120 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
FAB-120
Therapeutic area:
Ophthalmology and optometry
|
 |
FUND. PROGRESO Y SALUD |
FIMABIS-17003 |
Biodrugs/ Drugs |
Central Nervous System |
Prevention and/or treatment of mental diseases related with alcohol |
1NRP |
|
FIMABIS-17003
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells |
Biodrugs/ Drugs |
Central Nervous System |
Treatment of infants for different neurogical disorders |
2RP |
|
FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
|
FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks |
Biodrugs/ Drugs |
Dermatology |
Treatment of ischemic ulcers and stretch marks |
2RP |
|
FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks
Therapeutic area:
Dermatology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
|
FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14003 |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Musculoskeletal disorders |
1NRP |
|
FIBICO-14003
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-18002 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Loss weight induction mediated by browning |
1NRP |
|
FIMABIS-18002
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-17016. Compositions capable of modulating the stimulation of endogenous GDNF for the treatment of neurodegenerative diseases |
Biodrugs/ Drugs |
Central Nervous System |
Treatment of neurodegenerative diseases |
2RP |
|
FISEVI-17016. Compositions capable of modulating the stimulation of endogenous GDNF for the treatment of neurodegenerative diseases
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
|
FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14002 |
Biodrugs/ Drugs |
Cancer |
Metastatic processes and resistant cancers |
1NRP |
|
FIBICO-14002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-18008 |
Biodrugs/ Drugs |
Central Nervous System |
Treatment for decreasing alcohol intake |
1NRP |
|
FIMABIS-18008
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-20001. ANTIVIRAL AGENTS FOR CORONAVIRUS |
Biodrugs/ Drugs |
Infections |
Treatment of COVID-19 |
2RP |
|
FISEVI-20001. ANTIVIRAL AGENTS FOR CORONAVIRUS
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-17009 |
Biodrugs/ Drugs |
Central Nervous System |
Depression treatment |
1NRP |
|
FIMABIS-17009
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-20002. Compounds for the treatment of sympathetic over-activation |
Biodrugs/ Drugs |
Central Nervous System |
Treatment of sleep apnea, heart failure, metabolic syndrome, high blood pressure and others |
2RP |
|
FISEVI-20002. Compounds for the treatment of sympathetic over-activation
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-13001 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD) |
2RP |
|
FIMABIS-13001
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FIBICO |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Others |
1NRP |
|
FIBICO
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13002 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
2RP |
|
FISEVI-13002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-16009 |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Muscular regeneration |
1NRP |
|
FIMABIS-16009
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD |
FIBAO-18007 |
Biodrugs/ Drugs |
Infections |
Dalbavancin in the treatment of bacterial infections of the respiratory tract in children and pediatric patients |
1NRP |
|
FIBAO-18007
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBAO-13007 |
Gene / Cell Therapy |
Cancer |
Cancer cells |
2RP |
|
FIBAO-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIBAO-17018 |
Biodrugs/ Drugs |
Cancer |
Composition capable of modulating the activity of ATF4 for the treatment of cancer |
1NRP |
|
FIBAO-17018
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
CABIMER-17001 |
Biodrugs/ Drugs |
Central Nervous System |
Treatment for injury-mediated neurodegenerative diseases |
1NRP |
|
CABIMER-17001
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIBAO-91 Melatonine Solution |
Biodrugs/ Drugs |
Infections |
Sepsis |
4PhII |
|
FIBAO-91 Melatonine Solution
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBAO-13014 Combination of Ketamine and Meperidine |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Mucositis |
3PhI |
|
FIBAO-13014 Combination of Ketamine and Meperidine
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-15008 |
Biodrugs/ Drugs |
Infections |
Viral infection |
1NRP |
|
FIMABIS-15008
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBAO-116 |
Biodrugs/ Drugs |
Analgesia & Pain |
Fibromyalgia |
3PhI |
|
FIBAO-116
Therapeutic area:
Analgesia & Pain
|
|
FUND. PROGRESO Y SALUD |
CABIMER-18004 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
1NRP |
|
CABIMER-18004
Therapeutic area:
Metabolic / Endocrinology
|
 |
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Blood and Lymphatic systems
Cancer |
Oncology / Haematological disorders |
3PhI |
Spain / US |
Advanced cell therapies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Mutli-target siRNA approach |
Gene / Cell Therapy |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) |
2RP |
|
Mutli-target siRNA approach
Therapeutic area:
Autoimmune & Inflammation
Kidney and Genitourinary system
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New generation of peptides |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry |
Chronic complications of Diabetes / Choric kidney disease |
2RP |
|
New generation of peptides
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Peptide derived from a natural compound |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Metabolic / Endocrinology |
Osteoporosis treatment |
1NRP |
|
Peptide derived from a natural compound
Therapeutic area:
Autoimmune & Inflammation
Metabolic / Endocrinology
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Ophthalmology and optometry |
Eye rare diseases |
4PhII |
Spain / Europe |
Advanced cell therapies
Therapeutic area:
Ophthalmology and optometry
|
 |
Fundacion MEDINA |
MDN-057/MDN-058/MDN-059 |
Biodrugs/ Drugs |
Infections |
Gram negative infections |
1NRP |
|
MDN-057/MDN-058/MDN-059
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0090 |
Biodrugs/ Drugs |
Cancer |
Pancreatic Cancer |
1NRP |
|
MDN-0090
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-0145; MDN-0146 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
1NRP |
|
MDN-0145; MDN-0146
Therapeutic area:
Central Nervous System
|
|
Fundacion MEDINA |
MDN-0147; MDN-0148 & MDN-0149 |
Biodrugs/ Drugs |
Cancer |
Melanoma |
1NRP |
|
MDN-0147; MDN-0148 & MDN-0149
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-005 |
Biodrugs/ Drugs |
Central Nervous System
Musculoskeletal Disorders |
Amyotrophic lateral sclerosis (ALS) |
1NRP |
|
MDN-005
Therapeutic area:
Central Nervous System
Musculoskeletal Disorders
|
|
Fundacion MEDINA |
MDN-088 |
Biodrugs/ Drugs |
Cancer |
Breast, Colon & Lung Cancer |
1NRP |
|
MDN-088
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-0109, MDN-110, MDN-111, MDN- 112 |
Biodrugs/ Drugs |
Infections |
Malaria |
1NRP |
|
MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-018 |
Biodrugs/ Drugs |
Infections |
Fungal Infections |
1NRP |
|
MDN-018
Therapeutic area:
Infections
|
 |
Highlight Therapeutics |
BO-112 |
Biodrugs/ Drugs |
Cancer |
Solid tumors
Patients with liver metastasis from colorectal cancer or gastric/gastro-esophageal junction cancer |
4PhII |
|
BO-112
Therapeutic area:
Cancer
|
 |
Histocell |
HC016 |
Biodrugs/ Drugs |
Central Nervous System |
Acute Spinal Cord Injury |
4PhII |
|
HC016
Therapeutic area:
Central Nervous System
|
|
Histocell |
HR004 |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone Regeneration |
4PhII |
|
HR004
Therapeutic area:
Musculoskeletal Disorders
|
|
Histocell |
HR016 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Acute Lung Injury |
3PhI |
|
HR016
Therapeutic area:
Respiratory and Pulmonary system
|
 |
Institut Quimic de Sarrià (IQS) |
Chondro-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure |
1NRP |
|
Chondro-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Institut Quimic de Sarrià (IQS) |
Cardio-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct |
1NRP |
|
Cardio-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
IRYCIS |
New compound for the treatment of isquemical stroke |
Biodrugs/ Drugs |
Central Nervous System |
Isquemic stroke |
1NRP |
Spain |
New compound for the treatment of isquemical stroke
Therapeutic area:
Central Nervous System
|
 |
Laminar Pharma |
LP205A1 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology |
Cardiovascular and Metabolic Diseases, CNS, |
1NRP |
|
LP205A1
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
|
|
Laminar Pharma |
LP226A1 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
2RP |
|
LP226A1
Therapeutic area:
Central Nervous System
|
|
Laminar Pharma |
LP561A1 |
Biodrugs/ Drugs |
Cancer |
Glioma and other solid tumours |
4PhII |
|
LP561A1
Therapeutic area:
Cancer
|
|
Laminar Pharma |
LPA181 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company |
2RP |
|
LPA181
Therapeutic area:
Central Nervous System
|
|
Laminar Pharma |
LP204A1 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems |
Inflammation, Cardiovascular |
1NRP |
|
LP204A1
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
|
|
Laminar Pharma |
LP30171 |
Biodrugs/ Drugs |
Cancer
Metabolic / Endocrinology |
Metabolic Diseases, cancer |
1NRP |
|
LP30171
Therapeutic area:
Cancer
Metabolic / Endocrinology
|
 |
Leukos Biotech |
LK-01 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
AML |
3PhI |
|
LK-01
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
 |
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System |
Friedreich's Ataxia |
4PhII |
|
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
|
|
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System
Kidney and Genitourinary system |
Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD) |
4PhII |
|
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
Kidney and Genitourinary system
|
|
Minoryx |
MIN-102 (leriglitazone) |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy) |
5PhIII |
|
MIN-102 (leriglitazone)
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
 |
NATAC |
Retriacyl |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinitis Pigmentosa |
5PhIII |
Europe |
Retriacyl
Therapeutic area:
Ophthalmology and optometry
|
 |
Neurofix |
NFX91 |
Biodrugs/ Drugs |
Others |
Sleep disorders |
1NRP |
|
NFX91
Therapeutic area:
Others
|
|
Neurofix |
NFX88 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
4PhII |
Spain |
NFX88
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
Neurofix |
NFX81 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injuries |
2RP |
Spain |
NFX81
Therapeutic area:
Central Nervous System
|
 |
ONA Therapeutics |
ONA-1 |
Biodrugs/ Drugs |
Cancer |
Advanced cancer |
1NRP |
|
ONA-1
Therapeutic area:
Cancer
|
 |
Oryzon |
Iadademstat (ORY-2001) selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
AML (Elderly Unfit) - Alice Study (Combo with Azacitidine) |
4PhII |
|
Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis (RR & SP) - Sateen Study monotherapy |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Aggression in BPD - Reimagine Study |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
HDAC-6/Other undisclosed |
Biodrugs/ Drugs |
|
Undisclosed |
2RP |
|
HDAC-6/Other undisclosed
Therapeutic area:
|
|
Oryzon |
Iadademstat (ORY-2001) selective LSD1 inhibitor |
Biodrugs/ Drugs |
Cancer |
SCLC (First Line Relapsed) - Clepsidra Study (Combo with Platinum/Etoposide) |
4PhII |
|
Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area:
Cancer
|
|
Oryzon |
ORY-3001 - selective LSD1 inhibitor |
Biodrugs/ Drugs |
Others |
Non-Oncological |
2RP |
|
ORY-3001 - selective LSD1 inhibitor
Therapeutic area:
Others
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease (Mild-Moderate) - Etheral Study monotherapy |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Aggression in ADHD - Reimagine Study |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Aggression is ASD - Reimagine Study |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
|
Oryzon |
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Aggression in AD - Reimagine-AD Study |
4PhII |
|
Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area:
Central Nervous System
|
 |
PaloBiofarma |
PBF-509 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Lung Cancer |
4PhII |
Spain |
PBF-509
Therapeutic area:
Cancer
Central Nervous System
|
|
PaloBiofarma |
PBF-999 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
3PhI |
Spain |
PBF-999
Therapeutic area:
Cancer
|
|
PaloBiofarma |
PBF680 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
4PhII |
Spain |
PBF680
Therapeutic area:
Respiratory and Pulmonary system
|
|
PaloBiofarma |
PBF-677 |
Biodrugs/ Drugs |
Digestive System |
Colitis |
4PhII |
Spain |
PBF-677
Therapeutic area:
Digestive System
|
|
PaloBiofarma |
PBF-1129 |
Biodrugs/ Drugs |
Cancer |
Lung Cancer |
3PhI |
Spain |
PBF-1129
Therapeutic area:
Cancer
|
 |
Peptomyc |
OMO-103 |
Biodrugs/ Drugs |
Cancer |
Therapy for NSCLC and breast cancer. |
2RP |
Spain |
OMO-103
Therapeutic area:
Cancer
|
 |
PharmaMar |
TRABECTEDIN + Radiotherapy |
Biodrugs/ Drugs |
Cancer |
Sarcoma |
4PhII |
Europe |
TRABECTEDIN + Radiotherapy
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Small Cell Lung Cancer 2nd line |
4PhII |
NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) + DOXORUBICIN |
Biodrugs/ Drugs |
Cancer |
Small Cell lung cancer |
5PhIII |
EU , LA & LATAM |
LURBINECTEDIN (PM1183) + DOXORUBICIN
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Endometrial cancer |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
Zepzelca |
Biodrugs/ Drugs |
Cancer |
Small cell Lung Cancer 2nd line |
6Reg. |
USA |
Zepzelca
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Ewing Sarcoma |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) + CPT 11 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
4PhII |
|
LURBINECTEDIN (PM1183) + CPT 11
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Mesothelioma |
4PhII |
|
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
4PhII |
EU & NA |
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
EU |
PM14
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian Cancer. |
5PhIII |
Europe |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer (Japan) |
3PhI |
Japan |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN |
Biodrugs/ Drugs |
Cancer |
Retroperitoneal L-Sarcoma |
4PhII |
Italy |
TRABECTEDIN
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
Japan |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
BRCA+Breast Cancer |
4PhII |
|
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
 |
REIG JOFRE |
P0265 |
Biodrugs/ Drugs |
Dermatology |
Skin infections |
5PhIII |
Spain, Mexico |
P0265
Therapeutic area:
Dermatology
|
|
REIG JOFRE |
P0223 |
Biodrugs/ Drugs |
Dermatology |
Skin infection |
6Reg. |
Spain |
P0223
Therapeutic area:
Dermatology
|
 |
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Calciphylaxis |
5PhIII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Peripheral Arterial Disease (dialysis) |
5PhIII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
 |
SOM Biotech |
SOM3355 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Chorea in Huntington's disease |
5PhIII |
Spain |
SOM3355
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1311 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Phenylketonuria |
2RP |
|
SOM1311
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
SOM Biotech |
SOM0061 |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
COVID-19 |
4PhII |
|
SOM0061
Therapeutic area:
Infections
Respiratory and Pulmonary system
|
|
SOM Biotech |
SOM0044 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Parkinson’s disease |
2RP |
|
SOM0044
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM0208 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Niemann-Pick |
2RP |
|
SOM0208
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
 |
Sylentis |
siRNA / SYL1801 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retina |
2RP |
|
siRNA / SYL1801
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Tivanisirán / SYL1001 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry Eye Syndrome |
5PhIII |
|
Tivanisirán / SYL1001
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Bamosiran / SYL040012 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Hypertension, Glaucoma |
4PhII |
|
Bamosiran / SYL040012
Therapeutic area:
Ophthalmology and optometry
|
 |
VCN Biosciences |
VCN-11 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
2RP |
|
VCN-11
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-02 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
1NRP |
|
VCN-02
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Pancreatic cancer |
3PhI |
Spain |
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Head & Neck Cancer |
3PhI |
Spain |
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Retinoblastoma |
3PhI |
Spain |
VCN-01
Therapeutic area:
Cancer
|
 |
VENTER PHARMA |
LacTEST 2,7 g |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
5PhIII |
|
LacTEST 2,7 g
Therapeutic area:
Digestive System
|
 |
Vivia Biotech |
Vivia 009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Central Nervous System |
Non Hodgkin Lymphoma, CNS |
2RP |
Europe |
Vivia 009
Therapeutic area:
Blood and Lymphatic systems
Central Nervous System
|
|
Vivia Biotech |
Vivia 011 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity, Diabetes |
1NRP |
|
Vivia 011
Therapeutic area:
Metabolic / Endocrinology
|
 |
ZENDAL |
MTBVAC |
Vaccines |
Infections
Respiratory and Pulmonary system |
MTBVAC is a live freeze dried vaccine based on a genetically attenuated strain of a clinical isolate of M. tuberculosis manufactured by BIOFABRI. MTBVAC is now in Phase 2a in newborns infants and a Phase2a in BCG-vaccinated adults in South Africa |
4PhII |
|
MTBVAC
Therapeutic area:
Infections
Respiratory and Pulmonary system
|